Stephen J.LurieMD, PhD, Senior EditorIndividualAuthorPhil B.FontanarosaMD, Executive Deputy EditorIndividualAuthor
Copyright 2000 American Medical Association. All Rights Reserved.
Applicable FARS/DFARS Restrictions Apply to Government Use.2000
In Reply: In our article, we raised all of
the concerns stated by Dr Vicini and colleagues. We stated that the median
follow-up was relatively short, that the Radiation Therapy Oncology Group1 and the European Organization for Research in the
Therapy of Cancer2 have documented a benefit
in survival for up to 3 years of adjuvant AST in patients with locally advanced
(not clinically localized) prostate cancer, that "no conclusions can be drawn
from a nonrandomized retrospective comparison," and that "Results from prospective
randomized trials currently underway are needed to validate these findings."
D'Amico AV. Biochemical Outcomes of Treatment for Prostate Cancer—Reply. JAMA. 2000;284(22):2869. doi:10.1001/jama.284.22.2869